live sessions
MST:
Mountain Standard Time
MST
:
Mountain Standard Time
Monday (February 23) Sessions
Live Now:
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
Upcoming:
FEB23
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
In and Out of the Capsid
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
Previous:
FEB23
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
In and Out of the Capsid
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
